Hamburg - On September 28, 2022, the University Clinic of Cologne, Germany, announced it has concluded a license and collaboration agreement with BioNTech to research new approaches against HIV.
The collaboration will combine the University's long-standing experience in identifying and testing novel approaches against the human immunodeficiency virus (HIV) with BioNTech's expertise in immunotherapies and the company's proprietary mRNA vaccine platform. The goal of the research collaboration is to develop new potential strategies against HIV and test them in further studies.
NEUWERK advised the University Clinic of Cologne on the transaction.
For more information, please see the University's press release.
About BioNTech:
BioNTech is a German biotechnology company based in Mainz that develop and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vacines against infectious diseases, and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small moleculeimmunomodulators as treatment options for cancer.
Advisors for University Clinic of Cologne: NEUWERK, Hamburg Börge Seeger, MLE, JSM, CLP (transaction lead, partner) Daniel Schuppmann (Associate)
About NEUWERK: NEUWERK was founded in 2016 by lawyers from Freshfields Bruckhaus Deringer and ROXIN in Hamburg. NEUWERK brings together specialists from the fields of labor law, corporate law/M&A, IP/IT, real estate law, litigation and white-collar criminal law/criminal compliance.
Press contact: For further questions please contact Dr. Sebastian Naber (sebastian.naber@neuwerk.legal), T +49 40 340 5757-30.
NEUWERK Rechtsanwälte PartG mbB, Gänsemarkt 35, 20354 Hamburg, Germany www.neuwerk.legal